Thozalinone

Thozalinone is a synthetic central nervous system stimulant that was first described in the mid-1960s and later marketed under the brand name Stimsen ^[1][6]. Chemically it is an oxazolinone (an oxazole derivative), placing it in the same structural family as the psychostimulants pemoline and fenozolone; on acid hydrolysis all three yield the common product 5-phenyl-2,4-oxazolidinedione, reflecting their shared oxazoline scaffold ^[6].

Thozalinone was introduced during the first wave of modern psychopharmacology as a stimulant with proposed antidepressant and anorectic uses. Its basic pharmacology was characterized in animal studies that compared it with amphetamine and examined its effects on locomotion, appetite, monoamine oxidase, and seizure threshold ^[1]. In behavioral pharmacology it was used as a reference dopaminergic stimulant because, like amphetamine, apomorphine, and DOPA, it reliably induces gnawing and other stereotyped behaviors that are blocked by neuroleptic (dopamine-blocking) drugs ^[5][7].

Clinically, thozalinone was tested as an antidepressant in a double-blind study of depressed outpatients and was evaluated as an appetite suppressant in patients with obesity, consistent with the stimulant profile shared by many anorectic agents of the period ^[2][4]. It was also studied for its interactions with the tricyclic antidepressants imipramine and desipramine, which facilitated its behavioral effects ^[3]. Thozalinone never achieved lasting clinical adoption and is now essentially obsolete; it is not an approved medicine in current use, and modern references to it appear mainly in historical, analytical, and research contexts ^[6].

Limited evidence

⚠️ Both human studies exist as records with no retrievable results. A double-blind trial in depressed outpatients was published in 1966 as a two-page report with no abstract, no participant count and no dose ^[2]. A 1971 Portuguese-language trial in obese patients is indexed under appetite depressants with no abstract and no outcome data ^[4]. Neither can be summarised beyond its title.

⚠️ AND THE ONE APPARENT HUMAN DOSE FIGURE IN THE LITERATURE BELONGS TO A DIFFERENT DRUG. The 1982 urine assay paper covers pemoline, fenozolone and thozalinone together, and the only quantitative statement in its abstract, concerning levels after a single 30 milligram dose, is pemoline's ^[6]. Quoting it here would put a fabricated human dose on this page.

There is no pharmacokinetic parameter of any kind for thozalinone: no half-life, peak time, bioavailability, protein binding or clearance. There is no registered trial. And although it was clearly marketed, under the brand Stimsen, no discontinuation date or reason is retrievable, so none is asserted.

Thozalinone is an obscure, decades-old stimulant with little modern safety data, so caution is warranted. Expect the usual dopaminergic-stimulant effects: restlessness, reduced appetite, and disrupted sleep if taken late. Being a catecholamine releaser, it should not be combined with MAOIs given hypertensive and serotonin risk, and it warrants care alongside other stimulants or with cardiovascular disease, since heart rate and blood pressure can rise. There is no meaningful long-term toxicology in people. Treat it as a research-chemical curiosity, dose earlier in the day, and keep amounts modest. Not medical advice.

Thozalinone is an oxazolinone psychostimulant developed in the 1960s, belonging to the same small chemical family as the better-known agent pemoline. It was investigated during an active period of psychopharmacology research into stimulant compounds, and was studied both as a candidate antidepressant intended to lift mood and drive and as an anorectic for the treatment of obesity. Early pharmacological characterization described it as an amphetamine-like central excitant that increased locomotor activity and suppressed appetite.

It later found a second life as a research tool in behavioral neuroscience: because it reliably produced dopamine-dependent gnawing and stereotyped behavior in rodents, investigators used it to probe dopaminergic function and neuroleptic-induced receptor supersensitivity. Thozalinone never achieved lasting clinical use and fell out of circulation decades ago; as a result, detailed modern mechanistic, pharmacokinetic, and safety data are limited, and much of what is documented derives from mid-twentieth-century pharmacology and later dopaminergic behavioral studies.

Thozalinone is a largely forgotten agent of the early psychopharmacology era that has drawn renewed curiosity as a stimulant research chemical. Historically it was of interest for its amphetamine-like energizing and appetite-suppressing effects, and among researchers it earned a niche reputation as a useful experimental probe of dopamine signaling, given how consistently it elicited dopamine-dependent behaviors in animal models.

Its clearest documented value today is scientific and historical rather than clinical. Candor is essential here: thozalinone was never established as a mainstream medicine, its human data are sparse and dated, and as an amphetamine-like stimulant its liabilities would be expected to include overstimulation and the potential concerns common to that class. Anyone encountering it should understand that it is a relic of an earlier research age with a thin modern evidence base rather than a validated therapeutic.